ที่มา: The Wall Street Journal
4 Aug 09
Dow Jones Newswires (4 Aug 09, Dooren) reports that on Aug. 3, the Food and Drug Administration announced that it "approved a new warning on Allergan Inc.'s...Botox and a similar product about the possibility of life-threatening breathing and swallowing problems, following up on" an April "announcement about tougher warnings." In addition to "signing off on a boxed warning for Botox and Myobloc, made by Solstice Neurosciences Inc.," the FDA "said it was changing the generic names for both products to avoid medication errors," even though "the brand names and product formulations are not changing." According to the FDA, "Botox's generic name is onabotulinumtoxinA, after previously being known as botulinum toxin type A, while Myobloc's name is rimabotulinumtoxinB, after previously being called botulinum toxin type B." The drug Dysport, approved in April, has the generic name of abobotulinumtoxinA.